论文部分内容阅读
1例80岁男性晚期食管癌患者因失去手术机会且放弃放、化疗,给予白细胞介素100万U入0.9%氯化钠注射液100 ml静脉滴注,1次/d;复方苦参注射液15 ml入0.9%氯化钠注射液250 ml静脉滴注,1次/d;雷尼替丁注射液50 mg入壶,2次/d。用药前实验室检查示丙氨酸转氨酶(ALT)44 U/L,天冬氨酸转氨酶(AST)24 U/L,胆碱酯酶(CHE)388 U/L,总胆红素(TBil)29.2μmol/L,直接胆红素(DBil)7.3μmol/L,间接胆红素(IBil)21.9μmol/L。用药4 d后ALT 72 U/L、AST 71U/L、γ-L-谷氨酰转移酶(γ-GT)74 U/L、CHE 3387 U/L,继而出现恶心、呕吐和黄疸等症状;用药29 d后ALT 83 U/L,AST 67 U/L,γ-GT 597 U/L,CHE 2734 U/L,碱性磷酸酶(ALP)151 U/L,TBil203.0 mol/L,DBil 102.5 mol/L,IBil 100.5 mol/L,白蛋白(ALB)32.6g/L。停用复方苦参注射液,给予保肝治疗。1个月后,患者恶心、呕吐及黄疸等症状缓解,复查肝功能:ALT 15 U/L,AST 21 U/L,γ-GT59 U/L,ALP 66 U/L,TBil 46.1 mol/L,DBil 16.2 mol/L,IBil 29.9 mol/L。
One 80-year-old male patient with advanced esophageal cancer who lost his or her chance of surgery and gave up radiotherapy and chemotherapy was given an intravenous infusion of 1 million interleukin 1 million U into 0.9% sodium chloride injection once a day for three days. Compound Kushen injection 15 ml into 0.9% sodium chloride injection 250 ml intravenous infusion, 1 / d; ranitidine injection 50 mg into the pot, 2 times / d. Laboratory tests before treatment showed that ALT 44 U / L, aspartate aminotransferase 24 U / L, CHE 388 U / L, total bilirubin TBil, 29.2μmol / L, DBil 7.3μmol / L, and IBil 21.9μmol / L. After 4 days of treatment, ALT 72 U / L, AST 71U / L, γ-L-glutamyl transferase (γ-GT) 74 U / L, CHE 3387 U / L, followed by nausea, vomiting and jaundice and other symptoms; After 29 d treatment, ALT 83 U / L, AST 67 U / L, γ-GT 597 U / L, CHE 2734 U / L, alkaline phosphatase (ALP) 151 U / L, TBil203.0 mol / L, DBil 102.5 mol / L, IBil 100.5 mol / L and albumin (ALB) 32.6 g / L. Disable Compound Kushen injection, give liver protection treatment. After 1 month, the symptoms of nausea, vomiting and jaundice were relieved. The liver function was examined: ALT 15 U / L, AST 21 U / L, γ-GT59 U / L, ALP 66 U / L, TBil 46.1 mol / DBil 16.2 mol / L, IBil 29.9 mol / L.